The study appears in the Journal of the Federation of American Societies for Experimental Biology.
Contact dermatitis is an uncomfortable skin condition — a reaction to certain allergens and other foreign substances. It’s characterized by hypersensitivity of the skin, inflammation, and intense itching. One of the most commonly encountered allergens is that produced by poison ivy, oak, and sumac. Contact dermatitis affects more than 10 million people a year in the United States. Itching associated with contact dermatitis is often resistant to treatment with antihistamines, and other treatment options have side effects or are ineffective.
The Yale team studied the scratching behavior in mice given allergens to induce inflammation and itching. The researchers found that mice without the TRPA1 protein, an ion channel that controls itch-sensing nerves, scratched much less and showed a much weaker allergic reaction.
“These findings support a central role for TRPA1 in controlling inflammation and the itch response in allergic contact dermatitis,” said lead author Sven-Eric Jordt, associate professor of pharmacology at Yale School of Medicine. “Drugs targeting TRPA1 and its regulators are promising leads as we try to identify new anti-itch treatments.”
Other authors are Boyi Liu, Jasmine Escalera, Shrilatha Balakrishna, Lu Fan, Ana Caceres, Eve Robinson, Aiwei Sui, and Christina Herrick of Yale; and Malcolm McKay and Michael McAlexander of GlaxoSmithKline Pharmaceuticals. The study was funded by grants from the National Institute of Environmental Health Sciences (R01 ES015056, U01 ES015674, and F31 ES015932).
Contact Helen Dodson [email protected] 203-436-3984